Moderna Inc said it had completed the enrollment of 30,000 participants in a late-stage study testing its experimental coronavirus vaccine, with over a third of the participants from communities of color – Reuters reports.
Over 25,650 participants have so far received their second shot of the vaccine candidate, mRNA-1273 – Reuters quotes the company.
The U.S. Food and Drug Administration requires at least two months of safety data after a full vaccination regime to review applications for emergency use authorization of an experimental vaccine.
See all the news
რატომ ვერ ვმართეთ კორონავირუსი? - #Forbesკვირა პროლოგი გიორგი ისაკაძე
Q&A: Ek Law Office
LVMH and Tiffany Agree on Lower Price for $16 Billion Takeover
Woman in Charge
Hualing FIZ: Four New International Companies to Establish Free Zone Businesses in Georgia
Focus on Georgia - ADB
Focus on Ganja Gap in Nagorno-Karabakh’s Regional Conflict
Scientific Community Calls for Action Against Lockdowns
Georgian Government seize foreign-owned asset, referred to International Arbitration
Studying Abroad Costs Georgian Students €10,000–15,000
Franco Frattini - Georgia, straying from the rule of law
Letter to the Newsweek Editor: 'Russia Determined to Wield Power in Georgia'
Caspiannews: Georgia’s Actions to Seize Foreign Company Disrupt Telecommunications Corridor Between Europe & Asia
Turkish cable manufacturer Koc Kablo has opened its first factory in Georgia
TBC Bank announces management change
EU Local Statement on recent public comments with regards to the German Ambassador to Georgia
Oil prices fall further on virus fears, U.S. crude stock build
Georgia reports 3 new cases of coronavirus and 7 recoveries
The trend of demand for holiday houses is emerging - a study of the real estate consumer market